Celltrion gets green light to sell Truxima in Australia
Celltrion said Friday it has won approval from an Australian regulator for the sale of its biosimilar drug Truxima.The Therapeutic Goods Administration accepted Celltrion’s application to sell the biosimilar to Roche’s MabThera, the company said. The antibody biosimilar is used in the treatment of a number of diseases, including rheumatoid arthritis and non-Hodgkin’s lymphoma, a type of leukemia.
With the approval, Truxima would be Celltrion’s second drug, after Remsima, to hit the Australian market, company sources said.
Yonhap
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)